1. Scrip

PARP Inhibitors: Rich Prospects And More Deals In Store?

 
• By Anju Ghangurde

There’s significant excitement around the potential of PARP inhibitors in the currently established indication of ovarian cancer, but the best is probably yet to come with expansion into other cancers, according to a biopharma advisory firm. This class of drugs is also expected to trigger M&A, putting the spotlight on firms like Tesaro and Clovis Oncology.

Big Fish
THE PARP INHIBITORS SEGMENT IS EXPECTED TO SEE MORE DEALS

Poly (ADP-ribose) polymerase (PARP) inhibitors are expected to bring about a paradigm shift in the treatment of solid tumors and M&A activity around this promising class of drugs may well be corollary, indicates a report by ProGrow Pharma Partners, an Indian life sciences advisory firm.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business